IDO Emerges As Clean Combo Partner, Rising Star At AACR
Clean safety profile for combination of IDO inhibitors with anti-PD-1 agents in early studies presented at the American Association for Cancer Research meeting contrasts with the toxicity-laden CTLA-4/PD-1 regimen in Bristol's Phase III CheckMate 067 study.
You may also be interested in...
Following failure of Incyte/Merck's epacadostat/Keytruda study, NewLink Genetics says it is reviewing its IDO clinical programs.
In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival endpoint regardless of PD-L1 expression, supporting a bid for expanded labeling.
Biomedtracker's review of ASCO abstracts revealed several drugs to watch outside of the immuno-oncology space at the annual cancer conference in Chicago, including market-expanding data for Roche's Perjeta and J&J's Zytiga, and Phase III data for AstraZeneca's PARP inhibitor Lynparza in breast cancer.